FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/04/065921 [Registered on: 18/04/2024] Trial Registered Prospectively
Last Modified On: 17/04/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Nutraceutical 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Comparing the effect of early versus delayed fortification of human milk in neonates weighing less than 1600 grams on time to reach full feeds -A Randomized Controlled Trial 
Scientific Title of Study   Early versus delayed fortification of human milk in Preterm Neonates-A Randomized Controlled Trial 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Kaifi Siddiqui 
Designation  DM Neonatology Resident 
Affiliation  National Institute of Medical Science and Research,Jaipur, Rajasthan 
Address  First floor, Department of Neonatology, near Neonatal Intensive care unit, NIMS Hospital, Jaipur, Rajasthan, India
First floor, Department of Neonatology, near Neonatal Intensive careunit, NIMS Hospital, Jaipur Rajasthan, India
Jaipur
RAJASTHAN
303121
India 
Phone  9004431284  
Fax    
Email  homealoned@yahoo.com  
 
Details of Contact Person
Scientific Query
 
Name  Gunjana kumar  
Designation  Assistant Professor  
Affiliation  National Institute of Medical Science and Research, Jaipur,Rajasthan 
Address  First floor, Department of Neonatology, near Neonatal Intensive care unit, NIMS Hospital,Jaipur, Rajasthan.India

Jaipur
RAJASTHAN
303121
India 
Phone  7073077130  
Fax    
Email  gunjanakumar@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Gunjana kumar  
Designation  Assistant Professor  
Affiliation  National Institute of Medical Science and Research, Jaipur,Rajasthan 
Address  First floor, Department of Neonatology, near Neonatal Intensive care unit, NIMS Hospital,Jaipur, Rajasthan.India

Jaipur
RAJASTHAN
303121
India 
Phone  7073077130  
Fax    
Email  gunjanakumar@gmail.com  
 
Source of Monetary or Material Support  
National Institute of Medical Science And Research,Jaipur- Delhi Highway, NH 11C , Jaipur,Rajasthan, India Pin code - 303121 
 
Primary Sponsor  
Name  National Institute of Medical Science And Research , Jaipur , Rajasthan 
Address  First floor, Department of Neonatology, near Neonatal Intensive care unit, NIMS Hospital, Jaipur ,Rajasthan. 
Type of Sponsor  Private medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr kaifi Siddiqui  National Institute of Medical Science And Research , Jaipur , Rajasthan  1st floor, Department of Neonatology Near Neonatal Intensive Care Unit, NIMS Hospital
Jaipur
RAJASTHAN 
9004431284

homealoned@yahoo.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee, NIMS University Rajasthan, Jaipur  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: E46||Unspecified protein-calorie malnutrition,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Delayed  Babies will be started on exclusive breastmilk within the first 7 days of life at 20ml/kg/day once hemodynamically stabilised. Feeds will be increased by 20 ml/kg/day till baby tolerates feeds of 100 ml/kg/day. The human milk fortifier will be introduced after baby tolerates feeds of 100/ml/kg/day. 
Intervention  Early  Babies will be started on exclusive breastmilk within the first 7 days of life at 20ml/kg/day once hemodynamically stabilised. Feeds will be increased by 20 ml/kg/day till baby tolerates feeds of 60 ml/kg/day. The human milk fortifier will be introduced after baby tolerates feeds of 60/ml/kg/day. 
 
Inclusion Criteria  
Age From  0.00 Day(s)
Age To  7.00 Day(s)
Gender  Both 
Details  1. Infants with birth weight (BW) ≤1600 g will be eligible for the study
2. Hemodynamically stable prior to randomization
3. Babies whose parents have given informed consent 
 
ExclusionCriteria 
Details  Any one of the following
1. Antenatally diagnosed GI malformation
2. Baby born with absence or reversal of end-diastolic flow on antenatal umbilical artery Doppler
3. Presence of major congenital anomalies or chromosomal abnormalities at birth.
4. Need of two vasopressor support at the time of randomization for more than 48 hrs of life, due to which Human Milk Fortifier cannot be introduced by day 7
5. Perinatal asphyxia in neonates with APGAR score less than 4 at 5 min
6. Died or are expected to die within 72 hours.
7. Mother is not intended or is unable to provide the mother’s own milk 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
To compare the time taken to reach full feeds (150 ml/kg/day sustained for at least 24 hrs) in neonates with birth weight ≤1600 grams randomized based on the timing of initiation of fortification of feeds(60ml/kg/day vs 100 ml/kg/day)  The subjects would be followed up till discharge or death 
 
Secondary Outcome  
Outcome  TimePoints 
To compare the outcome in terms of-
1. Incidence of feed intolerance
2. Incidence of NEC
3. Incidence of sepsis
4.Total duration of intravenous fluid usage
5. Time of regaining birth weight
6.Total duration of hospital stay
7. Weight gain per kg per day at 1 month of age
8. Extrauterine growth retardation (EUGR) at 36 weeks PMA or at discharge
9. All-cause mortality
10.Incidence of neonatal morbidities including ventilator days, postnatal steroid treatment, chronic lung disease, patent ductus arteriosus, severe intraventricular haemorrhage (grade III and IV), periventricular leukomalacia, and retinopathy of prematurity  
The subjects would be followed up till discharge or death 
 
Target Sample Size   Total Sample Size="160"
Sample Size from India="160" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   30/04/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  30/04/2024 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

     

Preterm birth places the infant at risk of nutritional emergency and results in interruption of growth. It is a challenge to sustain in-utero growth velocity in preterm infants due to difficulty in maintaining adequate protein‒energy supplementation and due to their catabolic state secondary to postnatal illnesses such as sepsis, necrotising enterocolitis (NEC), chronic lung disease, need for assisted ventilation, and exposure to postnatal steroids.

 

Preterm infants are often deprived of in-utero nutrient accretion. This in-utero deprivation with additional nutrient deficit in postnatal life often results in postnatal growth failure.  The rate of extrauterine growth restriction (EUGR) at discharge is unacceptably high, ranging from 23% in infants born at 34 weeks’ gestation to 71% in those born at 23 weeks’ gestation.

Growth failure can continue even after discharge and has been associated with both short and long-term consequences including stunting, neurodevelopmental impairment, and early onset of adult diseases such as hypertension, diabetes, obesity, and hypercholesterolaemia.

 

Early aggressive nutrition is the norm in the management of preterm infants. Total parenteral nutrition being quiet demanding in terms of logistic required and on contrary, each day without enteral nutrition increases the likelihood of EUGR. Human milk (HM) is the best enteral food for preterm infants. However, unfortified human milk may not provide adequate protein to support growth and lean body mass accretion in very low birth weight infants.

Hence, enteral feeds should be started early, and full enteral feeds should be achieved as soon as possible. However, the composition of human milk varies throughout the course of lactation, and the unfortified human milk does not provide sufficient amounts of protein, calcium, and phosphorus necessary to achieve adequate growth of preterm infants8,9 leading to metabolic complications such as hypoproteinemia and osteopenia.

 

On average, unfortified human milk provides 67 kcal and 1.1 g protein per 100 mL, while human milk with human milk fortifier (HMF) provides 80 kcal and 2 g protein per 100 mL. A recent Cochrane meta‐analysis showed that fortification of human milk with multi‐component HMF improved in‐hospital growth rates; however, there was no significant difference in other major clinical outcomes. However, there is no consensus on timing to introduce HMF in enterally fed preterm infants attributed to a ‘lack of evidence and a strong local tradition’.13 As common practice most clinicians prefer adding HMF once the infant is on full enteral feeds generally defined as 150 ml/kg/day. Many units have preferred adding HMF at smaller feed volumes for the potential growth benefit to neonates. However, there are concerns relating to feed intolerance and increased hospital stay on adding early HMF in view of exposing an immature gut to high osmolarity. 

Various eminent organisations including the European Milk Bank Association (EMBA) Working group and National Neonatology Forum India, 2022 guidelines have recommended the addition of HMF for preterm neonates with birth weight <1800g to as early as the feed volume of 50-80 ml/kg/day.

Extremely low birth weight (ELBW) infants take 16 ± 7 days to regain birth weight16. The first 2 postnatal weeks delineate a critical period for growth and development and provide an opportunity to prevent energy and protein deficits along with fat-free mass (FFM) accretion in critically ill preterm neonates..Adding the HMF in the enteral feeds early could mitigate this gap of protein and energy deficit and can avoid the consequences associated with poor postnatal growth, which may also have adverse neurodevelopment outcomes. However, this benefit needs to be balanced against the risk associated with exposing the immature gut to the high osmolarity of fortified feeds that in turn, increases the risk of feed intolerance and Necrotising enterocolitis (NEC).

Hence the randomised controlled trial is planned to assess the safety and effects on growth of early fortification of human milk versus late fortification in preterm infants.

 
Close